352 related articles for article (PubMed ID: 18260640)
1. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for ASPP2 recognition by the tumor suppressor p73.
Canning P; von Delft F; Bullock AN
J Mol Biol; 2012 Nov; 423(4):515-27. PubMed ID: 22917970
[TBL] [Abstract][Full Text] [Related]
3. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding.
Tichý V; Navrátilová L; Adámik M; Fojta M; Brázdová M
Biochem Biophys Res Commun; 2013 Apr; 433(4):445-9. PubMed ID: 23501101
[TBL] [Abstract][Full Text] [Related]
4. Dimerization of the core domain of the p53 family: a computational study.
Madhumalar A; Jun LH; Lane DP; Verma CS
Cell Cycle; 2009 Jan; 8(1):137-48. PubMed ID: 19106606
[TBL] [Abstract][Full Text] [Related]
5. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
[TBL] [Abstract][Full Text] [Related]
6. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
Pivonková H; Pecinka P; Cesková P; Fojta M
FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908
[TBL] [Abstract][Full Text] [Related]
7. Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements.
Ethayathulla AS; Nguyen HT; Viadiu H
J Biol Chem; 2013 Feb; 288(7):4744-54. PubMed ID: 23243311
[TBL] [Abstract][Full Text] [Related]
8. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
[TBL] [Abstract][Full Text] [Related]
9. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells.
Adámik M; Bažantová P; Navrátilová L; Polášková A; Pečinka P; Holaňová L; Tichý V; Brázdová M
Biochem Biophys Res Commun; 2015 Jan; 456(1):29-34. PubMed ID: 25446071
[TBL] [Abstract][Full Text] [Related]
10. p53 and p73 display common and distinct requirements for sequence specific binding to DNA.
Lokshin M; Li Y; Gaiddon C; Prives C
Nucleic Acids Res; 2007; 35(1):340-52. PubMed ID: 17170001
[TBL] [Abstract][Full Text] [Related]
11. Tracing the protectors path from the germ line to the genome.
Coutandin D; Ou HD; Löhr F; Dötsch V
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15318-25. PubMed ID: 20696896
[TBL] [Abstract][Full Text] [Related]
12. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
Zawacka-Pankau J; Kostecka A; Sznarkowska A; Hedström E; Kawiak A
Cell Cycle; 2010 Feb; 9(4):720-8. PubMed ID: 20160513
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR
Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014
[TBL] [Abstract][Full Text] [Related]
14. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity.
Sauer M; Bretz AC; Beinoraviciute-Kellner R; Beitzinger M; Burek C; Rosenwald A; Harms GS; Stiewe T
Nucleic Acids Res; 2008 Apr; 36(6):1900-12. PubMed ID: 18267967
[TBL] [Abstract][Full Text] [Related]
15. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A
Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287
[TBL] [Abstract][Full Text] [Related]
16. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
Zhang L; Nie L; Maki CG
Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
[TBL] [Abstract][Full Text] [Related]
17. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
Vilgelm A; El-Rifai W; Zaika A
Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
[TBL] [Abstract][Full Text] [Related]
19. High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53.
Klein C; Georges G; Künkele KP; Huber R; Engh RA; Hansen S
J Biol Chem; 2001 Oct; 276(40):37390-401. PubMed ID: 11477076
[TBL] [Abstract][Full Text] [Related]
20. Differences in the transactivation domains of p53 family members: a computational study.
Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
